Skip to content
2000
Volume 29, Issue 29
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

A homomultimeric radioligand is composed of multiple identical ligands connected to the linker and radionuclide to detect a variety of overexpressed receptors on cancer cells. Multimer strategy holds great potential for introducing new radiotracers based on peptide and monoclonal antibody (mAb) derivatives in molecular imaging and therapy. It offers a reliable procedure for the preparation of biological-based targeting with diverse affinities and pharmacokinetics. In this context, we provide a useful summary and interpretation of the main results by a comprehensive look at multimeric radiopharmaceuticals in nuclear oncology. Therefore, explanations for the strategy mechanisms and the main variables affecting the biodistribution results will be explained. The discussion is followed by highlights of recent work in the targeting of various types of receptors. The consequences are expressed based on comparing some parameters between monomer and multimer counterparts in each relevant section.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867329666220420131836
2022-09-01
2024-12-26
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867329666220420131836
Loading

  • Article Type:
    Review Article
Keyword(s): homomultimer; PET; Radiolabeled peptide; RGD; SPECT; tumor targeting
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test